GSK touts expectations for 14 late-stage pipeline drugs

GlaxoSmithKline ($GSK) rolled out its late-stage drug prospects today, putting its best foot forward with a pair of drugs aimed at cancer and heart disease. Altogether, the pharma giant says it expects to post pivotal data on 14 therapeutics in the next two years. Report